Director/PDMR Shareholding

 ("Abcam" or "the Company")

Director's Dealings

Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, announces the following transactions undertaken by Directors of the Company:

On 16 March 2010, Jim Warwick, an Executive Director of the Company, exercised share options over 22,142 ordinary shares of 1 pence each in the Company at an exercise price of 280 pence per share. Following this transaction, Mr Warwick's total beneficial interest in the Company is 880,052 ordinary shares representing approximately 2.45 per cent. of the current issued share capital of the Company. 

For further information please contact:

Notes for editors:

About Abcam plc

Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with subsidiaries in Cambridge, Massachusetts, Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies and related products to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the antibodies are sold under the Abcam brand name. Abcam's mission is to develop the largest catalogue of the best antibodies in the world, with the vision of becoming a global leader in the wider protein detection and regulation markets. Abcam now has a rapidly growing online catalogue and as at 31 December 2009 it contained 57,960 products, most of which are antibodies, from over 250 suppliers. Abcam employs 250 staff in its four operating companies.